Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review.

European urology oncology·2026
Same author

Spinal glial cell derived extra-pituitary prolactin contributes to postoperative pain in females.

Frontiers in aging neuroscience·2026
Same author

Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy.

EMBO molecular medicine·2026
Same author

Sex-related gene expression in the posterodorsal medial amygdala of cycling female rats along with prolactin modulation of lordosis behavior.

Brain research·2025
Same author

mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions.

Cell death & disease·2023
Same author

Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to Antioxidant Therapy.

The American journal of pathology·2023

Related Experiment Video

Updated: Apr 20, 2026

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

2.9K

Prolactin-induced prostate tumorigenesis.

Lucila Sackmann-Sala1, Vincent Goffin

  • 1Inserm U1151, Institut Necker Enfants Malades, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, lucila.sackmann-sala@inserm.fr.

Advances in Experimental Medicine and Biology
|December 5, 2014
PubMed
Summary

Prolactin (PRL) significantly contributes to prostate cancer progression by activating STAT5. Targeting the prolactin receptor (PRLR)/STAT5 pathway offers a promising therapeutic strategy for prostate cancer treatment.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.3K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.2K

Related Experiment Videos

Last Updated: Apr 20, 2026

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

2.9K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.3K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.2K

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • The precise physiological role of prolactin (PRL) in the prostate remains unclear.
  • While genetic models haven't revealed a key regulatory function, substantial evidence links PRL to prostate tumorigenesis.

Purpose of the Study:

  • To investigate the role of prolactin (PRL) and its signaling pathway, particularly STAT5, in prostate cancer.
  • To explore the potential of targeting the PRL receptor (PRLR)/STAT5 axis as a therapeutic strategy for prostate cancer.

Main Methods:

  • Analysis of genetically-modified mouse models.
  • Examination of PRL and STAT5 expression in human prostate tumors.
  • Investigation of transgenic PRL expression in mouse prostate tissue.

Main Results:

  • PRL activation of STAT5 promotes prostate cancer cell and tissue growth and survival.
  • Clinical data show PRL expression and STAT5 activation correlate with prostate cancer severity.
  • Local PRL signaling, not systemic, appears crucial for disease progression.
  • Transgenic PRL in mouse prostates caused hyperplasia, dysplasia, and amplified stem cells.

Conclusions:

  • The PRLR/STAT5 signaling pathway is implicated in prostate cancer progression.
  • Targeting PRLR/STAT5, via antagonists, blocking antibodies, or JAK2 inhibitors, presents a potential therapeutic avenue.
  • Further research is needed to validate these therapies and elucidate PRL/STAT5-mediated mechanisms.